Janssen Pharmaceutica to expand production of Sirturo in Russia

12 March 2018

Janssen Pharmaceutica, which is part of US healthcare giant Johnson & Johnson (NYSE: JNJ), plans to increase production of its Sirturo (bedaquiline) –an anti-tuberculosis drug – in Russia, at the capacities of a local drugmaker Pharmstandard, according to recent statements of the companies, reportsThe Pharma Letter’s local correspondent.

The drug is already produced by Janssen in Russia and it is planned that additional production capacities will be established at the facilities of Russian drugmaker Pharmstandard’s Ufa Vitamin Plant. The increase of production will allow Janssen to significantly expand the geography of supplies of Sirturo worldwide.

Details of the contract are not disclosed.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK